BioCentury
ARTICLE | Clinical News

FDA approves less frequent dosing for BMS's Opdivo

March 9, 2018 6:35 PM UTC

FDA approved an sBLA for Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to include dosing every four weeks for most of the anti-PD-1 mAb’s approved indications and a shorter infusion time for all of its indications. The company said it is the only immuno-oncology therapy that allows for a four-week dosing schedule.

The agency approved a 480 mg dose of Opdivo, which is given every four weeks. The drug is already approved at a 240 mg dose, given every two weeks...